Related Experiment Video
Updated: May 28, 2026

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
Published on: February 3, 2023
The Dual Roles of Gut Microbiota in Biliary Atresia: Mechanisms, Biomarker Potential, and Therapeutic Implications
Jianing Yan1, Li Jiang1, Yating Li1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China.
Insights
Biliary atresia (BA) involves gut microbiome changes impacting liver health. While some microbes worsen BA, others may protect the liver, but more research is needed for clinical use.
Area of Science:
- Gastroenterology and Hepatology
- Microbiology
- Immunology
Background:
- Biliary atresia (BA) is a severe infant liver disease leading to failure without early intervention.
- The standard Kasai hepatoportoenterostomy (KPE) surgery has limitations, with many patients experiencing complications.
- The gut-liver axis and gut microbiota are increasingly recognized as key players in BA's progression.
Purpose of the Study:
- To review the dual role of gut microbiota in biliary atresia (BA).
- To summarize microbiome signatures before and after Kasai hepatoportoenterostomy (KPE).
- To critically evaluate microbiota-based biomarkers and interventions for BA.
Main Methods:
- Literature review of studies on gut microbiota in biliary atresia.
- Analysis of evidence regarding the gut-liver axis in BA pathogenesis.
- Evaluation of current and potential microbiota-based therapies.
Main Results:
- Gut dysbiosis in BA can impair the intestinal barrier, increase MAMPs translocation, and promote liver injury.
- Beneficial gut microbes and metabolites may protect the liver by maintaining barrier function and immune homeostasis.
- Specific microbiome signatures exist in BA, varying before and after KPE.
Conclusions:
- Gut microbiota significantly influences biliary atresia progression and outcomes.
- Microbiota-based biomarkers and interventions show promise but require further validation.
- Standardized prospective studies are essential before clinical implementation.
Abstract:
Biliary atresia (BA) is a progressive fibroinflammatory cholangiopathy of infancy that rapidly advances to cholestasis, fibrosis, cirrhosis, and liver failure if bile drainage is not restored early. Although Kasai hepatoportoenterostomy (KPE) remains the standard first-line operation, many children still develop recurrent cholangitis, persistent cholestasis, and progressive native liver injury. Increasing evidence indicates that the gut microbiota participates in this clinical course through the gut-liver axis. In BA, dysbiosis may weaken the intestinal barrier, increase translocation of microbe-associated molecular patterns (MAMPs), amplify innate and adaptive immune activation, disturb bile acid signaling, and promote fibrogenic and ferroptosis-related injury. In contrast, beneficial taxa and their metabolites may preserve epithelial integrity, support immune tolerance, maintain bile acid homeostasis, and constrain oxidative stress. This review summarizes current evidence on these contrasting harmful and protective effects, stage-specific microbiome signatures reported before and after KPE, and critically evaluates the present status of microbiota-based biomarkers and interventions. We emphasize that although several microbial signatures and therapeutic approaches are promising, they are not yet ready for routine clinical implementation and require prospective validation with standardized endpoints.
Related Concept Videos
Microbiota Modulation by Antibiotics
Gut-Brain Axis
Dysbiosis of the Gut Microbiota
Functions of the Gut Microbiota
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the small...
Development of Human Microbiota
